Member Info for Laura2022

Looks like 58p breaking

Clarets

See Trench summary of the Proactive where it outlined the process that will be updated on including the DoseMeRx Jv

13.25p to buy

Share Holders 2/12/24

National Wealth Fund 24.7%

Schroders plc 18.3%

Premier Miton 4.3%

Janus Henderson 3.7% (Own Goal no RNS yet breached 3% a long ago was waiting but they announced today they may still be accumulating)

Herald Investment Management 3.7%

In Total now Institutions/etc have breached 80% General Public 19%

Nothing available as funds hold 60%+

The chart was very oversold and now ready to move back above recent 19p high

Invinity will be holding a global webinar series for potential customers and partners commencing Thursday 12 December.

Grshaw

I sold some at 19p last month from my 10p average but am now adding that back as we speak

Was very interesting

Now it all becomes clear how Marren won the CEO power struggle. His mate Howard was at the NWF and is now on board with IES. This is starting to get very interesting. Why has Howard made that jump? He is betting it's going to make him very wealthy.

Also seems to have alligned with the charts bottoming at 11.5p after pull back from 20p

This news is a real game changer

He's spent 5yrs+ on INSP

I filtered him 18nths ago

Jambone

He clearly got burned on the corrupt INSP which did 20years doing nothing

Jonathan Marren, Chief Executive Officer at Invinity said:

 

"I'm delighted to officially launch ENDURIUM, our next-generation vanadium flow battery. As a Company, our activities are focused on accelerating global progress towards net zero and today's launch marks another important step forward in unlocking low-cost, low-carbon energy on demand for all.

 

"The commercial release of ENDURIUM is an important milestone for Invinity and an essential step on our pathway to profitability. We would not have achieved this without the hard work and dedication of every member of the Invinity team and the support of our partners, customers and shareholders along the way. Thank you to everyone who has helped make ENDURIUM a reality. I'm very excited for the next stage in our journey."

 

Stay up to date with news from Invinity. Join the distribution list for the Company's monthly investor newsletter here.

 

Enquiries:

With a long term view till mid 2025 TIG offers incredible opportunities

They also later say that cancellation of share purchases might occur which is even better

Sept 2024

The Buyback Programme commences today and will end on the earlier of the date upon which the aggregate number of Ordinary Shares purchased is 13,048,000, the aggregate consideration paid for Ordinary Shares reaches £19,572,000, the date of the Company's next annual general meeting (expected to be in April 2025) or 1 July 2025 (the "Buyback Period")

Yes I agree Trench

He was sharp focused and energised

Going concern

The Company is confident that given the health benefits and economics that MT-RNR1 will be a commercial success. The NICE EVA (Early Value Assessment) recommendation is testimony to it and the funding for the EVA evidence generation is expected to see over £0.5m of revenue commencing in November 2024.

The huge success of our CYP2C19 product development, offers the NHS an intervention that is estimated to save the NHS £160m every year and improve patient outcomes. This paves the way to a much larger global market than MT-RNR1 with a far less complex route to adoption. The NICE DAP (Diagnostics Assessment Programme) recommendation and the initial first sale demonstrates significant progress.

The Company recognises the uncertainty regarding the timing of the associated revenue generation, given we are at the forefront of the emerging pharmacogenetic field and the funding complexities within the NHS are understood. National Commissioning of our products brings significant upside to the sales forecasts, but it is outside of our control and therefore the timing is difficult to predict.

The various forecast scenarios that were considered by the Board, identify costs mitigations that could extend the cash runway, and the Directors have reasonable confidence in their ability to raise additional financing if required to bridge the funding gap to a positive EBITDA position. While the Board has a successful track record in raising funds, there remains uncertainty as to the amount of funding that could be raised from shareholders or debt providers.

As described in the accounting policies, we continue to adopt a going concern basis for the preparation of the accounts, but the combination of the above factors represent a material uncertainty that may cast significant doubt on the Group and Company's ability to continue as a going concern.

Great to see

It says last cash position at half year report only £39k?

But what is that 27% actually worth in monetary/assert value .

Thanks

What is the connection with BLU and satoshi please

Now £100k bought by directors